Novartis (NVS) just secured one of those FDA approvals that makes Wall Street sit up straighter and actuaries reach for stronger coffee, as regulators cleared Itvisma, a one-time gene replacement therapy for spinal muscular atrophy (SMA) in patients two years and older,…
